Topic Editors

Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
Prof. Dr. Patricia Rieken Macêdo Rocco
Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Centro de Ciências da Saúde, Avenida Carlos Chagas Filho, 373, Bloco G-014, Ilha Do Fundão, Rio de Janeiro 21941-598, Brazil

Acute Respiratory Distress Syndrome (ARDS): Personalized Therapies and Beyond, 2nd Edition

Abstract submission deadline
31 October 2025
Manuscript submission deadline
31 December 2025
Viewed by
1219

Topic Information

Dear Colleagues,

Acute respiratory distress syndrome (ARDS), which is characterized by severe inflammation and impaired gas exchange, presents a serious issue in critical care. Although supportive care has advanced, death rates are still high, highlighting the critical need for individualized treatment plans. The goal of this multidisciplinary topic is to examine novel strategies for managing ARDS, with a focus on the significance of customizing therapies to each patient's unique profile. Among the many subjects covered by the contributions are the use of sophisticated imaging methods to track lung function, the significance of genomes and biomarkers in forecasting treatment response, and the use of machine learning algorithms in therapeutic decision-making. Furthermore, new pharmaceuticals and supplemental therapy including immunomodulatory therapies and extracorporeal membrane oxygenation (ECMO) will be discussed. This Topic aims to shed light on the route to more efficient, individualized treatment for ARDS patients, eventually leading to better outcomes and an improvement in quality of life, by encouraging multidisciplinary collaboration and exchanging state-of-the-art research. Pre-clinical experimentation, clinical studies, reviews, and perspectives are all welcome for submission.

Dr. Denise Battaglini
Prof. Dr. Patricia Rieken Macêdo Rocco
Topic Editors

Keywords

  • acute respiratory distress syndrome
  • ARDS
  • acute respiratory failure
  • personalized therapies, subphenotypes

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Clinics and Practice
clinpract
1.7 2.6 2011 20.8 Days CHF 1600 Submit
Journal of Clinical Medicine
jcm
3.0 5.7 2012 16 Days CHF 2600 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
12 pages, 1384 KiB  
Article
Comparison of COVID-19 and Non-COVID-19 Tracheostomised Patients: Complications, Survival, and Mortality Risk Factors
by Marta Mesalles-Ruiz, Maitane Alonso, Marc Cruellas, Martí Plana, Anna Penella, Alejandro Portillo, Víctor Daniel Gumucio, Xavier González-Compta, Manel Mañós and Julio Nogués
J. Clin. Med. 2025, 14(2), 633; https://doi.org/10.3390/jcm14020633 - 19 Jan 2025
Viewed by 880
Abstract
Objectives: To compare the outcomes of tracheostomised COVID-19 patients with non-COVID-19 tracheostomised patients to identify factors influencing severity and mortality. Methods: A retrospective, single-centre cohort study was conducted on COVID-19 tracheostomised patients admitted from May 2020 to February 2022, compared with a cohort [...] Read more.
Objectives: To compare the outcomes of tracheostomised COVID-19 patients with non-COVID-19 tracheostomised patients to identify factors influencing severity and mortality. Methods: A retrospective, single-centre cohort study was conducted on COVID-19 tracheostomised patients admitted from May 2020 to February 2022, compared with a cohort of non-COVID-19 tracheostomised patients. Results: COVID-19 tracheostomised patients had a higher mortality rate (50% vs. 27.3% in non-COVID-19 patients). Mortality risk factors in COVID-19 tracheostomised patients included female sex (HR 1.99, CI 1.09–3.61, p = 0.025), ischemic heart disease (HR 5.71, CI 1.59–20.53, p = 0.008), elevated pre-tracheostomy values of PEEP (HR 1.06, CI 1.01–1.11, p = 0.017) and INR (HR 1.04, CI 1.01–1.07, p = 0.004), and ventilatory complications (HR 8.63, CI 1.09–68.26, p = 0.041). No significant differences in complication rates were found based on Sars-CoV-2 infection or tracheostomy type. Conclusions: Tracheostomy technique did not impact complications, discharge circumstances, or mortality, supporting the safety of bedside percutaneous tracheostomies for COVID-19 patients. COVID-19 tracheostomised patients exhibited a higher mortality rate. Full article
Show Figures

Figure 1

Back to TopTop